key: cord-0854031-1zgrnibc
authors: Hsueh, Sung-Ju; Lee, Ming-Jen; Chen, Hsin-Shui; Chang, Kai Chieh
title: Myopathy Associated with COVID-19
date: 2020-08-03
journal: J Formos Med Assoc
DOI: 10.1016/j.jfma.2020.07.042
sha: d40ceca29c85111497ed540d97e66422ee0dede4
doc_id: 854031
cord_uid: 1zgrnibc

nan

Myopathy Associated with COVID-19 SARS-CoV-2, a novel pathogen causing COVID-19, had been reported to cause many extra-respiratory presentations. We would like to report a possible neuromuscular manifestation of SARS-CoV-2 infection.

The patient is a 51-year-old Taiwanese lady with the history of hypertension and obesity (body mass index 34.9.) There was no past history of neuromuscular disorders. She had been travelling with a tour group in Europe before the admission, and was noted to have fever (38.2 ) upon arriving in Taiwan. PCR for SARS-CoV-2 returned positive, and she was subsequently hospitalized on March 15 th , 2020.

On admission, her consciousness and physical examination were normal. Chest Roentgenogram revealed increased infiltration and consolidation in the right lung field. She had progressive dyspnea and was intubated on March 18 th . During the admission, Rosuvastatin 5 mg/day was administered from March 20 th to April 1 st , and Cisatracurium 8 mg/hour was administered from March 24 th to April 7 th . Other medications included azithromycin, meropenem, lopinavir/ritonavir, hydroxychloroquine, baricitinib and sedative agents. She was extubated on April 9 th without complication. The PCR for SARS-CoV-2 became negative since April 6 th .

The patient remained quadriplegic in the following days. Gradual improvements of muscle power occurred since April 17 th , with symmetrical weakness over the limbs (proximal limbs MRC grading 2/5, distal limbs 3/5). Improvements occurred gradually, and she was able to walk with support of caregiver on May 1 st . Myalgia was not reported throughout the whole course.

On examination, the upper limbs were normoreflexic and the lower limbs were hyporeflexic, with slightly diffuse hypotonia. There were no observable fasciculation or significant atrophic change. The pinprick sensation was intact, and the vibratory sensation was mildly decreased in the ankles.

The creatine kinase (CK) level became elevated since April 2 nd , which peaked on the next day (2949 U/L) and returned to normal range on April 12 th . Another episode of CK elevation occurred from April 16 th to 20 th , with maximum of 4294 U/L (supplementary table 1 

Guillain-Barré Syndrome Associated with SARS-CoV-2

Guillain-Barré syndrome related to COVID-19

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

We thank the medical, nursing, and support staff of Units 2A and 7B for taking care of the patient.Study funding: None.Disclosure: The authors have nothing to disclose.